StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report released on Thursday. The brokerage issued a hold rating on the stock.
LadRx Stock Performance
LadRx has a 52-week low of $0.05 and a 52-week high of $0.86. The company's fifty day moving average is $0.09.
Get LadRx alerts:LadRx Company Profile
(Get Rating)
LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.Read More
- Get a free copy of the StockNews.com research report on LadRx (CYTR)
- MarketBeat Week in Review – 2/6 – 2/10
- Will Snowflake Have Tough Sledding, Trying To Keep Rally Alive?
- The Bottom Is In For Cloudflare Stock
- 3 Tickers Leading a Meme Stock Revival
- Microsoft-Activision Blizzard Merger: Navigating Risk and Reward
Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.